Cigna’s Express Scripts is reportedly in discussions to settle claims by the Federal Trade Commission that pharmacy benefit managers steered patients to higher‑priced insulin to capture rebates. The FTC has paused proceedings and is considering a proposed consent agreement that could resolve claims against Cigna’s subsidiaries, while also engaging CVS and UnitedHealth in parallel talks. The development comes after the FTC’s 2024 lawsuit naming the three largest PBMs and follows industry countersuits; a settlement would mark the first resolution in a case that could reshape PBM contracting and insulin pricing dynamics.